Broadway Entertainment has formed a strategic partnership with Jilin University.

2021 Year 10 Month 22 On the same day, Jilin Province Bodaweiye Pharmaceutical Co., Ltd. and the School of Pharmacy at Jilin University held a ceremony in Changchun titled "Jilin University School of Pharmacy - The establishment ceremony of the "Jilin Province Bodaweiye Pharmaceutical Co., Ltd. Joint Science and Technology Innovation Fund" and the donation ceremony for the "Bodaweiye Scholarship at Jilin University School of Pharmacy" marked the formalization of a strategic partnership between the two parties, under which they will: School-Enterprise Co-built Laboratory Leading players in the field are joining forces to collaborate on multifaceted talent development and project partnerships, aiming to meet both the market's demand for innovative drugs and society's need for top-tier expertise.

Bo Da Weiye General Manager Xie Wenbo (left) and Dean of the School of Pharmacy at Jilin University, Ma Jie (right), jointly signed the strategic cooperation agreement.

Both parties have highly praised this strategic collaboration. Xie Wenbo, General Manager of Boda Weiye, stated: "Benefiting from the increasingly favorable policy environment in recent years and the momentum of open collaboration in domestic new drug research and development, this strategic partnership with the School of Pharmacy at Jilin University is poised to unlock even more innovative products that will ultimately benefit patients. This is a win-win collaboration rooted in a spirit of synergy, and we are filled with confidence and excitement about the promising future ahead."

Xie Wenbo, General Manager of Bobo Weiye, Delivers a Speech

Ma Jie, Dean of the School of Pharmacy at Jilin University, commented: “Both parties will, based on their strong mutual trust, actively advance cooperation in new drug research and development as well as the commercialization of research outcomes. Together, they will strive to establish a leading position in the chemical pharmaceutical and biopharmaceutical industries, leveraging their respective strengths and engaging in comprehensive collaboration through various models. By jointly building an innovative industry-academia-research partnership framework, they aim to foster mutual growth—where expertise and industry complement each other—and drive shared development. Ultimately, they will work toward creating a model for successful university-enterprise collaboration by maximizing resource sharing and capitalizing on each other’s competitive advantages.”

Ma Jie, Dean of the School of Pharmacy at Jilin University, delivers a speech.

Both parties engaged in an in-depth discussion on two key agreements: the establishment of a joint research fund for tackling critical scientific challenges and the creation of endowed scholarships. They explored specific details such as the project approval process for collaborative research initiatives, the eligibility criteria for student scholarships, and strategies for cultivating high-level talent through joint training programs that directly benefit enterprises. Furthermore, the two sides reached a robust strategic partnership covering areas like jointly developing university-enterprise joint laboratory projects aimed at technological innovation, offering undergraduate and graduate scholarships, and fostering comprehensive talent development initiatives. Both parties unanimously agreed that the signing of this cooperation agreement will undoubtedly catalyze the continuous growth and deepening of their comprehensive strategic partnership, paving the way for a new era of co-creation and mutual success between the university and industry.

Currently, China's pharmaceutical market places particular emphasis on innovation. On one hand, the government is expanding the centralized procurement of existing products whose patents have expired. On the other hand, it is accelerating the approval and scaling-up of new drugs still under patent protection, while also broadening their coverage under medical insurance. These measures have effectively addressed the challenge of drug accessibility. Moreover, with continuous policy enhancements, this supportive environment plays a crucial role in fostering the healthy growth of outstanding projects—and represents significant positive news for companies like Bodaweiyue, which remain committed to creating lasting value.

Ma Jie, Dean of the School of Pharmacy at Jilin University, Qu Yuanli, Secretary of the Party Committee, Liu Lihui, Deputy Secretary of the Party Committee and Vice Dean, as well as Vice Deans Wang Yi, Cao Xia, and Guan Qingxiang—along with other members of the leadership team—attended the signing ceremony. Also present were Zhang Xiping, Director of the Research Office, and several project leaders who submitted applications for the joint research initiative. Meanwhile, Xie Wenbo, General Manager of Jilin Province Bodaweiye Pharmaceutical Co., Ltd., along with Chief Scientist Li Xiaodong, Chief Consultant Wang Ensi, Assistant to the General Manager Tian Kuo, Project Manager Wang Xiaoyu, and Senior Researcher Xie Jing, participated in the meeting.